StockNews.AISignal intelligence
Zymeworks Inc. · NYSE · Healthcare
Browse public ZYME signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Phase 3: Ziihera plus chemotherapy showed statistically significant survival benefit. Regulatory submission is targeted for 2026, enabling a clear approval pathway. Companies plan label expansion and expect partnership milestone revenues. Positive data could materially affect ZYME if it retains rights or royalties.
View signal analysisZymeworks discontinues clinical development of ZW171 T-cell engager for cancer. Decision based on poor benefit-risk profile from Phase 1 trial data. Ongoing Phase 1 trial participants will continue treatment per investigator's discretion. Company prioritizes resources on ZW251 and other products in pipeline. ZYME stock dropped 5% to $14.07 following the news.
View signal analysisZymeworks halts experimental cancer drug development due to disappointing trial results.
View signal analysisZYME reported a Q4 loss of 31 cents per share, missing expectations. Sales of $31.03 million fell short of $45.2 million consensus. ZYME prioritizes ZW251 for hepatocellular carcinoma, IND submission planned for 2025. ZW220 Phase 1 studies paused despite encouraging preclinical data. Ziihera received accelerated FDA approval for biliary tract cancer treatments.
View signal analysis- Zymeworks Inc. reported a quarterly loss of $0.42 per share, missing estimates. - Revenue for March 2024 was $10.03 million, falling short of expectations by 44.22%. - Zymeworks has outperformed consensus EPS estimates two out of the last four quarters. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis